NCIC CLINICAL TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: WREN

SATURDAY, APRIL 27, 2013 – 11:00 AM – 3:45 PM

CHAIR: F. SAAD

(03:45 PM – 04:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.
- To provide a learning environment supportive to new investigators.
- To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

11:00 pm WELCOME

F. Saad

11:10 pm NCIC CTG/INTERGROUP PHASE III TRIALS: OPEN

PR.13 (RADICALS)/MRC PR.10 C. Catton/F. Saad
PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only F. Saad/M. Gleave

NCIC CTG/INTERGROUP PHASE III TRIALS: CLOSED, PENDING ANALYSES

BL.8/EORTC 30994 F. Saad/L. Wood
REC.2/ECOG E2805 Sunitinib/placebo vs. Sorafenib/placebo vs. placebo in resected RCC M. Jewett/ L. Wood
PRC.2/CALGB 90202 Early vs. Standard Zoledronic Acid in CaP metastatic to bone F. Saad

11:30 pm NCIC CTG IND TRIALS: OPEN.

IND.205: PX-866 in recurrent or metastatic CRPC S. Hotte
IND.209: Reolysin in combination with docetaxel and prednisone or docetaxel and prednisone alone in metastatic CRPC B. Eigl

continued on next page …
11:50 pm **NCIC CTG IND TRIALS: CLOSED.**
IND.195: A Phase II Study of SB 939 in Patients with CRPC  B. Eigl

11:55 pm **NCIC CTG IND REPORT**  K. Chi

12:00 pm **LUNCH**

1:30 pm **UPDATE ON NCIC CTG APPROVED STUDIES**
- PR.15 Pilot Study of HDR Brachytherapy in Intermediate Risk CaP  E. Vigneault/ A. Loblaw
- BL.12 A Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma  K. Sridhar

1:50 pm **CUOG Update**

2:00 pm **Invited Lecture:** Personalized Genomic Approaches and Pathway Identification for Individualized Prostate Cancer Therapy  R. Bristow

2:30 pm **DOG REPORTS/NEW PROPOSALS**
- Localized Prostate Cancer  A. Loblaw/ N. Fleshner
- Advanced Prostate Cancer  K. Chi/ F. Saad
- Advanced Bladder  S. North/ W. Kassouf
- Kidney  A. Kapoor/ J. Knox
- Testes  C. Kollmaansberger/ P. Chung
- Superficial bladder  A. So

3:45 pm **Meeting Adjourned**

**3:45 PM – 4:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED**